BMI View: High inflation has undermined foreign drugmakers'' profitability in Argentina''s pharmaceuticalmarket. The potential currency devaluation will further erode the returns of foreign investment.Nevertheless, some multinationals continue to invest in the country, as its market size, relatively welldevelopedlocal manufacturing force and its strategic location mean Argentina remains an appealingprospect..Headline Expenditure Projections:Pharmaceuticals: ARS39.4bn (US$8.7bn) in 2012 to ARS49.4bn (US$8.9bn) in 2013; +25.3% in localcurrency terms and 2.7% in US dollar terms. The forecast figures remain the same as in Q213....
No comments:
Post a Comment